Oncolytics Biotech is directing a broad clinical trial program with the objective of developing REOLYSIN® as a human cancer therapeutic. The current clinical program includes human trials using REOLYSIN® alone and in combination with chemotherapy or immune modulation, and delivered via local administration and/or intravenous administration. The Company's first pivotal trial will be a Phase III randomized clinical trial examining the intravenous administration of REOLYSIN® in combination with paclitaxel and carboplatin in patients with platinum-failed head and neck cancers.
| REO 020 |
Intravenous administration in combination with paclitaxel and carboplatin |
Phase II metastatic melanoma |
U.S. |
Ongoing |
| REO 016 |
Intravenous administration in combination with paclitaxel and carboplatin |
Phase II non-small cell lung cancer |
U.S. |
Ongoing |
| REO 015 |
Intravenous administration in combination with paclitaxel and carboplatin |
Phase II head and neck |
U.S. |
Ongoing |
| REO 014 |
Intravenous administration monotherapy |
Phase II sarcomas |
U.S. |
Complete |
| REO 013 |
Intravenous administration monotherapy (sponsored by University of Leeds) |
Translational metastatic colorectal |
U.K. |
Ongoing |
| NCI Trial |
Intravenous administration monotherapy (NCI) |
Phase II melanoma |
U.S. |
Ongoing |
| NCI Trial |
Intravenous and intraperitoneal administration monotherapy (NCI) |
Phase I/II ovarian |
U.S. |
Ongoing |
| REO 012 |
Intravenous administration in combination with cyclophosphamide |
Advanced malignancies including pancreatic, lung, ovarian |
U.K. |
Ongoing |
REO 011
(Phase II) |
Intravenous administration in combination with paclitaxel and carboplatin |
Phase II head and neck |
U.K. |
Complete |
| REO 011 |
Intravenous administration in combination with paclitaxel and carboplatin |
Advanced malignancies including melanoma, lung, ovarian |
U.K. |
Complete |
| REO 010 |
Intravenous administration in combination with docetaxel |
Advanced malignancies including bladder, prostate, lung, upper gastro-intestinal |
U.K. |
Complete |
| REO 009 |
Intravenous administration in combination with gemcitabine |
Advanced malignancies including pancreatic, lung, ovarian |
U.K. |
Complete |
| REO 008 |
Local therapy in combination with radiation |
Phase II various metastatic tumours, including head & neck |
U.K. |
Complete |
| REO 007 |
Infusion monotherapy |
Phase I/II recurrent malignant gliomas |
U.S. |
Ongoing |
| REO 006 |
Local therapy in combination with radiation |
Phase I various metastatic tumours |
U.K. |
Complete |
| REO 005 |
Intravenous administration monotherapy |
Phase I various metastatic tumours |
U.K. |
Complete |
| REO 004 |
Intravenous administration monotherapy |
Phase I various metastatic tumours |
U.S. |
Complete |
| REO 003 |
Local monotherapy |
Phase I recurrent malignant gliomas |
Canada |
Complete |
| REO 002 |
Local monotherapy |
T2 prostate cancer |
Canada |
Complete |
| REO 001 |
Local monotherapy |
Phase I trial for various subcutaneous tumours |
Canada |
Complete |
